Device for delivering drugs to meibomian glands

Abstract

The invention discloses a device for delivering medicine to the meibomian glands, which includes a handle, a treatment head, and a meibomian gland drug delivery patch. A control system is installed in the handle, and the treatment head is detachably connected to the meibomian gland. On the upper end of the handle, an electromagnet is arranged in the treatment head, and the meibomian gland drug delivery patch is magnetically connected with the treatment head through the electromagnet, and the meibomian gland drug delivery patch is provided on the left side. There is a microneedle drug delivery component, the drug layer is arranged inside the microneedle drug delivery component, and the electromagnetic control module of the control system intermittently controls the power on and off of the electromagnet to drive the treatment head and the meibomian gland The dosing patch is intermittently clamped and released on the patient's upper and lower eyelids. The invention has the advantages of fast and efficient administration, comfort and convenience, reasonable design, good therapeutic effect, safe and painless drug delivery, and the like.

Description

technical field [0001] The invention belongs to the technical field of ophthalmic medical devices, and in particular relates to a device for delivering medicine to meibomian glands. Background technique [0002] When the meibomian glands develop lesions, it is necessary to deliver drugs to the meibomian glands for treatment. For example, the common meibomian gland dysfunction (MGD) is a chronic and diffuse meibomian gland abnormality with many causes and complex pathogenesis. It has a high prevalence and has become one of the common ocular surface diseases in clinical practice. Its treatment has become a hot spot and difficult point in clinical research in recent years, mainly including improving lifestyle, physical therapy, drug therapy, and surgical treatment, of which drug therapy plays an important role . Drugs for the treatment of MGD can be roughly divided into three categories according to the etiology and pathogenesis. The first category is to improve tear quality ...

AI Technical Summary

Problems solved by technology

[0004] In 2011, the International Workshop on Meibomian Gland Dysfunction (IWMGD) proposed a hierarchical treatment strategy for MGD in its report, pointing out that patients with MGD above grade two should be given necessary drug therapy. The specific graded treatment of MGD is: grade one, The clinical description is that the symptoms are not obvious, and mild abnormalities are found in the examination, and the treatment methods are health education and physical therapy; the second level, the clinical description is mild discomfort and moderate abnormalities in the clinical examination, and the treatment methods are increased on the basis of the first level Topical drugs, including artificial tears and antibiotic eye drops or ointments; grade III, clinically described as frequent symptoms, moderate abnormality of the meibomian glands, treatment is based on grade II plus glucocorticoid anti-inflammatory drugs and promoting Oral drugs for lipid metabolism; grade 4, the clinical description is that the symptoms persist and are unbearable, and the meibomian gland is severely abnormal accompanied by ocular surface abnormalities. The treatment method is to cooperate with the corresponding complication treatment on the basis of grade 3. , although there is physical therapy for meibomian gland dysfunction, it is only used as an adjuvant therapy, and drug therapy for meibomian gland dysfunction is still the first choice. At present, although oral medicine and direct use of artificial tears, antibiotic eye drops or Eye ointment and other treatment methods, but for the treatment of meibomian gland dysfunction, the effect is not good, such as oral administration, the onset of effect is slow due to low blood drug concentration, the treatment cycle is long, and long-term use of antibiotic eye drops or eye ointment, etc. It will cause drug-induced damage to the corneal epithelium and damage the microbial environment on the ocular surface. Therefore, how to quickly and efficiently deliver drugs to the meibomian glands for treatment is still a difficult problem

Images